Valarie Tan is a reporter for Bloomberg 1. Hilary Rowland The 33-year old self-taught programmer is the CEO of eClick Hilary Rowland (I don't think Mary can do this) Position:CEO of eClick Interactive Inc and NewFaces.com The sexy Hilary Rowland is the head of Project Migration in eClick Interactive Inc. This 33-year old is a self-taught programmer that set foot in the business world at the quite young age 15. She is a great charity worker too. She is known to have sold her jewelry designs to eliminate poverty in Africa.
It’s in my Robinhood account, it’s a anti-pureneric autism and spectrum drug developer. Highly volatile. Why is ISEE going nuts?
Iveric Bio Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy IVERIC bio, Inc. (Nasdaq: ISEE) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for avacincaptad pegol (ACP, also known as Zimura®), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to Age-Related Macular Degeneration (AMD). To date, ACP is the first and only investigational therapy to receive Breakthrough Therapy designation status for this indication, which was granted based on the 12-month pre-specified primary endpoint data in the GATHER1 and GATHER2 pivotal clinical trials. Breakthrough Therapy designation is designed to accelerate the development and regulatory review of potential new medicines that are intended to treat a serious condition and address a significant unmet medical need. The new medicine needs to show preliminary clinical evidence that the drug may demonstrate substantial improvement in effectiveness or safety over available therapies on a clinically significant endpoint and in general, should show a clear advantage.1 “We believe this Breakthrough designation reflects the fact that both GATHER1 and GATHER2 met their primary endpoint with a safety profile that meets the stringent criteria required,” said Glenn P. Sblendorio, Chief Executive Officer of Iveric Bio. “We are now focused on the execution of our full NDA submission and launch preparation, with the possibility of being first to market. We look forward to working collaboratively with the FDA to expedite the review timeline for avacincaptad pegol and to potentially bringing a new therapy to AMD patients impacted by GA.”
Ted My wife is always like why are you watching Asian Bloomberg the market is closed. Is it? I get my Singapore updates from Sixuan Li Sixuan Li presents the Global Market Reports from Singapore.
I mentioned KenC because his threads on 3x lev ETFs have low credibility among Elite because of rage and topics best kept off the Stock Threads. You keep things classy, maybe politics should be avoided because they’re not conducive to fun. Edited: to be more coherent, it’s early!
Iveric bio announces FDA granted breakthrough designation for Zimura 16:04 ISEE IVERIC bio "announced that the FDA has granted Breakthrough Therapy designation for avacincaptad pegol - ACP, also known as Zimura - a novel investigational complement C5 inhibitor for the treatment of geographic atrophy secondary to Age-Related Macular Degeneration. To date, ACP is the first and only investigational therapy to receive Breakthrough Therapy designation status for this indication, which was granted based on the 12-month pre-specified primary endpoint data in the GATHER1 and GATHER2 pivotal clinical trials." Glenn P. Sblendorio, CEO, says: "We believe this Breakthrough designation reflects the fact that both GATHER1 and GATHER2 met their primary endpoint with a safety profile that meets the stringent criteria required. We are now focused on the execution of our full NDA submission and launch preparation, with the possibility of being first to market. We look forward to working collaboratively with the FDA to expedite the review timeline for avacincaptad pegol and to potentially bringing a new therapy to AMD patients impacted by GA."